Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CODX 
Co-Diagnostics Inc (CODX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: CODX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 8.02% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.61M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 2 | Beta 0.79 | 52 Weeks Range 0.23 - 1.40 | Updated Date 09/16/2025 |
52 Weeks Range 0.23 - 1.40 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4946.14% |
Management Effectiveness
Return on Assets (TTM) -38.09% | Return on Equity (TTM) -63.4% |
Valuation
Trailing PE - | Forward PE 16 | Enterprise Value 1481290 | Price to Sales(TTM) 13.56 |
Enterprise Value 1481290 | Price to Sales(TTM) 13.56 | ||
Enterprise Value to Revenue 1.48 | Enterprise Value to EBITDA 0.52 | Shares Outstanding 38523600 | Shares Floating 35890110 |
Shares Outstanding 38523600 | Shares Floating 35890110 | ||
Percent Insiders 7.88 | Percent Institutions 13.46 |
Upturn AI SWOT
Co-Diagnostics Inc
Company Overview
History and Background
Co-Diagnostics, Inc. was founded in 2013. It focuses on developing and commercializing molecular diagnostic solutions, primarily for infectious diseases.
Core Business Areas
- Molecular Diagnostics: Development, manufacturing, and sales of real-time polymerase chain reaction (PCR) diagnostic tests.
- Equipment: Development, manufacturing, and sales of real-time PCR instruments.
Leadership and Structure
Dwight Egan serves as the CEO. The company operates with a management team overseeing various departments, including research, development, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Logix Smart COVID-19 Test: A PCR test for detecting SARS-CoV-2. High demand during the pandemic. Competitors include Roche, Abbott, and Thermo Fisher Scientific. Revenue significantly impacted by the decreased demand after the pandemic. Market share is difficult to quantify precisely due to the fragmented nature of the diagnostics market but was significant during peak COVID-19 testing periods.
- Logix Smart ABC Test: A multiplex test for influenza A/B and COVID-19. Competitors include Roche, Abbott, and QuidelOrtho. Limited market share data available.
- CoDx Box: A PCR instrument used with the company's tests. Competitors include Thermo Fisher Scientific, Bio-Rad, QIAGEN.
Market Dynamics
Industry Overview
The molecular diagnostics industry is experiencing growth driven by technological advancements, increasing prevalence of infectious diseases, and rising demand for personalized medicine. It is highly competitive with many players across different segments.
Positioning
Co-Diagnostics focuses on affordable and accessible molecular diagnostics, particularly in emerging markets. Their competitive advantage lies in their patented CoPrimer technology. Its patented CoPrimeru2122 technology has the ability to enhance PCR diagnostics.
Total Addressable Market (TAM)
The global molecular diagnostics market is estimated to be around $10 billion annually. Co-Diagnostics aims to capture a portion of this market through its affordable tests and expansion into new geographic regions.
Upturn SWOT Analysis
Strengths
- Patented CoPrimer technology
- Focus on affordable diagnostics
- Established presence in emerging markets
- Agility in developing new tests
Weaknesses
- High reliance on COVID-19 testing revenues
- Smaller scale compared to major competitors
- Limited brand recognition compared to established players
Opportunities
- Expanding test menu beyond infectious diseases
- Entering new geographic markets
- Partnerships with larger healthcare companies
- Developing point-of-care diagnostic solutions
Threats
- Intense competition from established players
- Price pressures in the diagnostics market
- Regulatory changes impacting test approval
- Decreasing COVID-19 testing demand
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Abbott (ABT)
- Thermo Fisher Scientific (TMO)
- QuidelOrtho (QDEL)
- Hologic (HOLX)
Competitive Landscape
Co-Diagnostics has the potential to fill a niche in accessible PCR diagnostic instruments and multiplex tests. They must continue to innovate and expand product offerings to compete with established players with larger market shares.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was driven by the surge in demand for COVID-19 testing. Growth trends have since normalized. Please see sec.gov for all official filings.
Future Projections: Future projections depend on the success of expanding the test menu and entering new markets. Please see sec.gov for all official filings.
Recent Initiatives: Recent initiatives include developing new diagnostic tests, expanding into new geographic regions, and focusing on molecular biology equipment, instruments and related products and accessories.
Summary
Co-Diagnostics benefited significantly from the COVID-19 pandemic, but its long-term success depends on diversifying its product offerings and expanding into new markets. Their Coprimer technology provides a competitive advantage, but they face intense competition. Reducing the company's dependency on Covid-19 related products is paramount. The company needs to expand its test portfolio to support long-term growth and value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Co-Diagnostics Inc. investor relations website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Co-Diagnostics Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2017-07-12 | Chairman & CEO Mr. Dwight H. Egan | ||
Sector Healthcare | Industry Medical Devices | Full time employees 132 | Website https://co-dx.com |
Full time employees 132 | Website https://co-dx.com | ||
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.